Shuttle Pharmaceuticals Issues 3.7M Shares and 17.9M Warrants After Merger Approval
SHPH sits 39% above its 52-week low of $2.576.
Summary
Shuttle Pharmaceuticals issued 3.7M shares from preferred conversions and 17.9M warrants (including 16.9M pre-funded warrants) following shareholder approval of the United Dogecoin merger.
Key Events · Financing and Capital Events · SHPH
-
Preferred Stock Conversions
Issued 2,869,595 shares from Series B-1 and 867,887 shares from Series B-2 Preferred Stock conversions, totaling 3,737,482 new common shares.
-
Warrant Issuance
Issued warrants for 927,114 shares at $10.30 exercise price (post-reverse split) and pre-funded warrants for 16,932,508 shares.
-
Massive Dilution Overhang
The 16.9M pre-funded warrants alone represent potential dilution far exceeding the company's current ~628K outstanding shares (based on $2.25M market cap at $3.58).
-
Follows Merger Approval
This issuance executes the share authorization approved at the September 9, 2026 special meeting, as reported in the September 11 8-K.
Analysis · SHPH · Life Sciences
The company has now issued 3,737,482 shares of common stock upon conversion of Series B-1 and B-2 Preferred Stock, plus warrants to purchase 927,114 shares at $10.30 and pre-funded warrants for 16,932,508 shares. This is the actual execution of the share issuance approved at the September 9 special meeting. The pre-funded warrants alone represent a potential 16.9 million additional shares — a massive overhang relative to the company's current market cap of roughly $2.25 million. The exercise price of $10.30 is nearly triple today's $3.58 stock price, meaning the regular warrants are deeply out of the money, but the pre-funded warrants carry a nominal exercise price and are effectively common stock equivalents. This is highly dilutive to existing shareholders.
How filings like this one have moved
In the 30 days to Sep 23, 2026, 35.1% of the 1081 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SHPH was trading at $3.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $2.58 to $55.90. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.